The FDA Promises a Custom-Fit Rulebook for Rare Disease Drugs. Patients Should Read the Fine Print.

The FDA’s new Rare Disease Framework Initiative promises evidence standards tailored to tiny patient populations. What it covers, how to weigh in on October 28, and the questions it leaves open.